These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 28538732)

  • 1. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
    Kim J; Hu Z; Cai L; Li K; Choi E; Faubert B; Bezwada D; Rodriguez-Canales J; Villalobos P; Lin YF; Ni M; Huffman KE; Girard L; Byers LA; Unsal-Kacmaz K; Peña CG; Heymach JV; Wauters E; Vansteenkiste J; Castrillon DH; Chen BPC; Wistuba I; Lambrechts D; Xu J; Minna JD; DeBerardinis RJ
    Nature; 2017 Jun; 546(7656):168-172. PubMed ID: 28538732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
    Kim J; Lee HM; Cai F; Ko B; Yang C; Lieu EL; Muhammad N; Rhyne S; Li K; Haloul M; Gu W; Faubert B; Kaushik AK; Cai L; Kasiri S; Marriam U; Nham K; Girard L; Wang H; Sun X; Kim J; Minna JD; Unsal-Kacmaz K; DeBerardinis RJ
    Nat Metab; 2020 Dec; 2(12):1401-1412. PubMed ID: 33257855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
    Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
    Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urea Cycle Sustains Cellular Energetics upon EGFR Inhibition in EGFR-Mutant NSCLC.
    Pham-Danis C; Gehrke S; Danis E; Rozhok AI; Daniels MW; Gao D; Collins C; Paola JTD; D'Alessandro A; DeGregori J
    Mol Cancer Res; 2019 Jun; 17(6):1351-1364. PubMed ID: 30808730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.
    Liu Y; Marks K; Cowley GS; Carretero J; Liu Q; Nieland TJ; Xu C; Cohoon TJ; Gao P; Zhang Y; Chen Z; Altabef AB; Tchaicha JH; Wang X; Choe S; Driggers EM; Zhang J; Bailey ST; Sharpless NE; Hayes DN; Patel NM; Janne PA; Bardeesy N; Engelman JA; Manning BD; Shaw RJ; Asara JM; Scully R; Kimmelman A; Byers LA; Gibbons DL; Wistuba II; Heymach JV; Kwiatkowski DJ; Kim WY; Kung AL; Gray NS; Root DE; Cantley LC; Wong KK
    Cancer Discov; 2013 Aug; 3(8):870-9. PubMed ID: 23715154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.
    Çeliktas M; Tanaka I; Tripathi SC; Fahrmann JF; Aguilar-Bonavides C; Villalobos P; Delgado O; Dhillon D; Dennison JB; Ostrin EJ; Wang H; Behrens C; Do KA; Gazdar AF; Hanash SM; Taguchi A
    J Natl Cancer Inst; 2017 Mar; 109(3):1-9. PubMed ID: 28376202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
    Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
    Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
    Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
    J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
    Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
    Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
    [No Abstract]   [Full Text] [Related]  

  • 10. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
    Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
    Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditional disruption of hepatic carbamoyl phosphate synthetase 1 in mice results in hyperammonemia without orotic aciduria and can be corrected by liver-directed gene therapy.
    Khoja S; Nitzahn M; Hermann K; Truong B; Borzone R; Willis B; Rudd M; Palmer DJ; Ng P; Brunetti-Pierri N; Lipshutz GS
    Mol Genet Metab; 2018 Aug; 124(4):243-253. PubMed ID: 29801986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer.
    Lee HM; Muhammad N; Lieu EL; Cai F; Mu J; Ha YS; Cao G; Suchors C; Joves K; Chronis C; Li K; Ducker GS; Olszewski K; Cai L; Allison DB; Bachert SE; Ewing WR; Wong H; Seo H; Kim IY; Faubert B; Kim J; Kim J
    Nat Metab; 2024 Jul; 6(7):1310-1328. PubMed ID: 38877143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
    Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
    Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.
    Zhang H; Nabel CS; Li D; O'Connor RÍ; Crosby CR; Chang SM; Hao Y; Stanley R; Sahu S; Levin DS; Chen T; Tang S; Huang HY; Meynardie M; Stephens J; Sherman F; Chafitz A; Costelloe N; Rodrigues DA; Fogarty H; Kiernan MG; Cronin F; Papadopoulos E; Ploszaj M; Weerasekara V; Deng J; Kiely P; Bardeesy N; Vander Heiden MG; Chonghaile TN; Dowling CM; Wong KK
    J Thorac Oncol; 2023 Jul; 18(7):882-895. PubMed ID: 36958689
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
    Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
    [No Abstract]   [Full Text] [Related]  

  • 17. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
    Moro M; Caiola E; Ganzinelli M; Zulato E; Rulli E; Marabese M; Centonze G; Busico A; Pastorino U; de Braud FG; Vernieri C; Simbolo M; Bria E; Scarpa A; Indraccolo S; Broggini M; Sozzi G; Garassino MC
    J Thorac Oncol; 2018 Nov; 13(11):1692-1704. PubMed ID: 30149143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
    Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
    J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose-6-phosphate dehydrogenase maintains redox homeostasis and biosynthesis in LKB1-deficient KRAS-driven lung cancer.
    Lan T; Arastu S; Lam J; Kim H; Wang W; Wang S; Bhatt V; Lopes EC; Hu Z; Sun M; Luo X; Ghergurovich JM; Su X; Rabinowitz JD; White E; Guo JY
    Nat Commun; 2024 Jul; 15(1):5857. PubMed ID: 38997257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
    Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.